The site uses anonymous third party analytic cookies: in accessing any element/area of the site outside of this banner, you consent to receiving cookies.

More Than Skin Deep: The Underlying Burdens of Psoriasis and Psoriatic Arthritis

More Than Skin Deep: The Underlying Burdens of Psoriasis and Psoriatic Arthritis

This report* was initiated and funded by Novartis Pharmaceuticals UK Ltd. Wilmington Healthcare was commissioned by Novartis to develop this report, which has been informed by input from experts working in Psoriasis and Psoriatic Arthritis, including leading clinicians and patient charities.

The report shines a light on the under-recognised impact of psoriasis and psoriatic arthritis (PsA) and the need to improve outcomes for those affected by these interlinked conditions. The foreword has been provided by Sir Paul Beresford MP, Conservative Member of Parliament for Mole Valley and former Chair of the All-Party Parliamentary Group on Skin.

This page is intended for UK healthcare professionals, other relevant decision makers including MPs.

Interested? Get in touch

The report, ‘More than Skin Deep: The Underlying Burdens of Psoriasis and Psoriatic Arthritis’ sets out the close link between psoriasis and PsA and the opportunities that exist to understand the personal, NHS and socioeconomic burdens of these conditions across the UK. The report has been developed in consultation with an Expert Working Group, who have provided invaluable insights into how health and care services are currently managing people affected by these conditions.

The report also sets out updated estimates of how many people are likely living with psoriasis and PsA across new NHS commissioning geographies and Parliamentary constituencies, to help inform local service planning and delivery.

The report makes a number of key recommendations for improving psoriasis and PsA outcomes, across the following five domains:

  • Prioritising psoriasis and PsA as interlinked conditions
  • Optimising service planning
  • Empowering people with psoriasis and PsA
  • Supporting the workforce
  • Recognising the wider impacts of psoriasis and PsA

“We are currently at a crossroads in the future of psoriasis and PsA care in this country – it is beholden upon us to rethink our approach and embrace the recommendations that will help to transform the lives of all those affected by these interlinked conditions.”

Sir Paul Beresford MP, Conservative Member for Mole Valley, Former Chair and Member of the All-Party Parliamentary Group on Skin

 

UK 174607 | January 2022

*We are grateful to the expert working group who participated in the development of this report through two psoriasis and psoriatic arthritis stakeholder workshops organised and funded by Novartis Pharmaceuticals UK Ltd., and those who reviewed the report and offered insightful feedback.